Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual MeetingPRNewsWire • 12/07/20
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingPRNewsWire • 11/11/20
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) CongressPRNewsWire • 11/04/20
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) CongressPRNewsWire • 10/29/20
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial MarketsPRNewsWire • 10/28/20
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19PRNewsWire • 10/27/20
Nektar (NKTR) Down 12% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/05/20
Nektar Looks Undervalued, But The Biggest Value-Driving Events Are Still In 2021Seeking Alpha • 08/28/20
Nektar Therapeutics (NKTR) CEO Howard Robin on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/20
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial MarketsPRNewsWire • 07/28/20
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)PRNewsWire • 06/04/20
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' JournalPRNewsWire • 05/22/20